ReviewChemistry & biodiversity2026
Nature's Hidden Arsenal: Unveiling the Anticancer Potential of Eugenia Species.
Review in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Eugenia comprises approximately 1050 species widely used in traditional medicine and human nutrition due to their diverse pharmacological properties. This review aimed to critically summarize the anticancer potential of Eugenia species and to correlate their biological activities with the presence of bioactive phytochemicals. Literature published between 2013 and 2025 was retrieved from PubMed, SciELO, and Google Scholar databases using terms related to Eugenia, cancer, antiproliferative, and cytotoxic activities. Increasing evidence has demonstrated the anticancer effects of selected Eugenia species in in silico, in vitro, and in vivo models against different cancer types. These effects are associated with multiple mechanisms, including apoptosis induction via caspase-3/7 activation and Fas receptor upregulation, inhibition of tumor cell migration and invasion through suppression of MMP-2 and MMP-9, and cell cycle arrest. The observed activities are closely related to the presence of flavonoids, phenolic acids, carotenoids, monoterpenes, triterpenes, and sesquiterpenes. Despite promising preclinical findings, limitations such as the scarcity of in vivo studies, lack of extract standardization, and absence of clinical trials still hinder the translational application of Eugenia-derived compounds in oncology. Future studies focusing on mechanistic elucidation, bioavailability, toxicity, and clinical validation are essential for the development of Eugenia-based anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.